Hydromethylthionine mesylate (HMTM), a stable reduced form of methylthioninium, has been shown to act as a selective inhibitor of tau protein aggregation in cell-free systems and in cellular and murine models of tauopathy [29,30,31]. This evidence concerns the gene MAPT and tauopathy.